VBLT Vascular Biogenics Ltd.

5.75
+0.10  (2%)
Previous Close 5.65
Open 5.65
Price To book 4.42
Market Cap 154688139
Shares 26,902,285
Volume 156,939
Short Ratio 2.07
Av. Daily Volume 177,145

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 trial met primary endpoint. Overall survival data released November 29, 2016 with full data released February 21, 2017.
VB-111
Thyroid cancer
Phase 3 trial to be initiated by end of 2017.
VB-111
Recurrent platinum resistant ovarian cancer
Phase 3 completion of enrollment announced January 6, 2017. Interim analysis released October 2, 2017 noted trial to continue as planned. Top-line data due 1Q 2018.
VB-111
Recurrent glioblastoma (rGBM) cancer
Phase 2 failed to meet endpoints - Feb 2015 data
VB-201
Ulcerative colitis
Phase 2 failed to meet endpoints - Feb 2015 data
VB-201
Psoriasis